Subsequent Events |
3 Months Ended |
|---|---|
Dec. 31, 2020 | |
| Subsequent Events | |
| Subsequent Events |
12. Subsequent Events On January 27, 2021, the Company entered into an Asset Purchase Agreement by and among the Company, NeuBase Corporation, the Company’s wholly-owned subsidiary, and Vera Therapeutics, Inc. (“Vera”). Pursuant to the terms of the Asset Purchase Agreement, the Company expects to acquire infrastructure, programs and intellectual property for several peptide-nucleic acid (PNA) scaffolds from Vera for total consideration of approximately $3.7 million, consisting of cash and a number of shares of the Company’s common stock to be determined at the closing of the acquisition. The transaction is expected to close in the first calendar quarter of 2021. |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|